Metabolic Fate of Sipoglitazar a Novel Oral PPAR Agonist with Activities for PPAR-γ, -α and -δ, in Rats and Monkeys and Comparison with Humans In Vitro

Sipoglitazar is a novel anti-diabetic agent with triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-γ, -α, and -δ. The bioavailability for sipoglitazar was 95.0% and 72.6% in rats and monkeys respectively and sipoglitazar is hardly subject to first pass metab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug metabolism and pharmacokinetics 2012, Vol.27 (2), p.223-231
Hauptverfasser:	Nishihara, Mitsuhiro, Sudo, Miyako, Kamiguchi, Hidenori, Kawaguchi, Naohiro, Maeshiba, Yoshihiro, Kiyota, Yutaka, Takahashi, Junzo, Tagawa, Yoshihiko, Kondo, Takahiro, Asahi, Satoru
Format:	Artikel
Sprache:	eng
Schlagworte:	ADME (absorption distribution, metabolism and excretion) Administration, Oral Animals glucuronidation Humans Macaca fascicularis Male Metabolic Clearance Rate - drug effects Metabolic Clearance Rate - physiology peroxisome proliferator-activated receptor (PPAR) pharmacokinetics PPAR alpha - agonists PPAR alpha - metabolism PPAR delta - agonists PPAR delta - metabolism PPAR gamma - agonists PPAR gamma - metabolism Propionates - administration & dosage Propionates - chemistry Propionates - metabolism Rats Rats, Sprague-Dawley sipoglitazar Species Specificity Thiazoles - administration & dosage Thiazoles - chemistry Thiazoles - metabolism Tissue Distribution - drug effects Tissue Distribution - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!